key: cord-0762612-jmizf3aq authors: Moreno, Gerard; Ruiz-Botella, Manuel; Martín-Loeches, Ignacio; Alvarez, Josep Gómez; Herrera, María Jiménez; Bodí, María; Armestar, Fernando; Parra, Asunción Marques; Estella, Ángel; Trefler, Sandra; García, Ruth Jorge; Paya, Josefa Murcia; Cortes, Pablo Vidal; Díaz, Emili; Ferrer, Ricard; Albaya-Moreno, Antonio; Socias-Crespi, Lorenzo; Goytisolo, Josep Maria Bonell; Chinesta, Susana Sancho; Loza, Ana; Espina, Lorena Forcelledo; Laderas, Juan Carlos Pozo; deAlba-Aparicio, María; Montori, Laura Sánchez; Perapoch, Immaculada Vallverdú; Hidalgo, Virginia; Gutiérrez, Virginia Fraile; Ortega, Ana Mª Casamitjana; Serrano, Fátima Martín; Nieto, Mercedes; Cortes, María Blasco; Marín-Corral, Judith; Solé-Violán, Jordi; Rodríguez, Alejandro title: A Differential Therapeutic consideration for use of Corticosteroids according to Established COVID-19 Clinical Phenotypes in Critically ill Patients date: 2021-10-26 journal: Med Intensiva DOI: 10.1016/j.medin.2021.10.002 sha: a21e8a6eeccf14c7f51f7b79622dffd5e48288f3 doc_id: 762612 cord_uid: jmizf3aq Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study Setting: Critical Care Units Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: corticosteroids vs no corticosteroids Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a Multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis(sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2,017 patients were analyzed, 1171(58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR:1.0,95%CI:0.98-1.15). Corticosteroids were administered in 298/537(55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR=0.85[0.55-1.33]). A total of 338/623(54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72[0.49-1.05]). Finally, 535/857(62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75[0.58-0.98]) and sHR (0.79[0.63-0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment. . The study sponsors have no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Objetivo: Evaluar si el uso de corticoesteroides (Cs) se asocia con la mortalidad en la unidad de cuidados intensivos (UCI) en la población global y dentro de los fenotipos clínicos predeterminados Diseño: Análisis secundario de estudio multicéntrico observacional Ámbito: UCI Pacientes: Pacientes adultos con COVID-19 confirmado ingresados en 63 UCIs de España Intervención: Corticoides vs. no Corticoides A partir del análisis no supervisado de grupos, 3 fenotipos clínicos fueron derivados y clasificados como: A: grave, B: critico and C: potencialmente mortal. Se efectuó un análisis multivariado después de un propensity optimal full matching (PS) y una regresión ponderada de Cox (HR) y análisis de Fine-Gray (sHR) para evaluar el impacto del tratamiento con Cs sobre la mortalidad en la población general y en cada fenotipo clínico. Resultados: Un total de 2.017 pacientes fueron analizados, 1.171(58%) con Cs. Después del PS, el uso de Cs no se relacionó significativamente con la mortalidad en UCI (OR:1.0,95%CI:0.98-1. 15 ). Cs fueron administrados en 298/537(55.5%) pacientes del fenotipo "A" y no se observó asociación significativa con la mortalidad Patients with COVID-19 are known to develop a major inflammatory response that can lead to acute respiratory distress syndrome (ARDS). As inflammation is thought to contribute to the pathogenesis of ARDS (1) it warrants further investigation as to the pharmacokinetic effects of immunomodulatory agents. Further study of the interaction of these drugs with virus/host dynamics is necessary to provide insight into optimal timing of administration, dosing, and association with other interventions. Corticosteroids are potent anti-inflammatory agents with immunomodulatory properties, which exert inhibitory effects in several stages of the inflammatory cascade, and consequently have been proposed for the treatment of ARDS (2-3). However, in recent epidemics due to coronavirus infections such as that Middle East respiratory syndrome-related coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome associated coronavirus (SARS-CoV) or influenza viruses the use of corticosteroids was associated with delayed virus clearance and an increase in ICU mortality (4) (5) (6) (7) . Several randomized control trials (8-10) found a benefit to the use of corticosteroids in patients with COVID-19, and various clinical guidelines (11,12) recommended its use to all patients requiring oxygen with severe COVID-19 during the second wave. However, there is limited data in relation to ICU admission beyond 28 days that assesses the side effects of medium-and long-term glucocorticoid treatment (13) (14) . For example, there are still unanswered questions as which subgroup or rather "phenotype' of patients could have higher response rate to the steroid therapy (15) . Therefore, our primary objective is to identify the association of corticosteroids treatment in a whole cohort population and according to three new classified clinical phenotypes identified from 2,017 COVID-19 critically ill patients in Spain (16) . Our secondary objective is to stratify the competing risk factors associated with use of corticosteroids in each phenotype and clinical outcome. A cluster is intrinsically homogeneous in the basis of the features used to generate the cluster. (18) The homogeneity in each cluster allows us to study the impact of a target treatment within clusters and relate that impact among each clusters' distinctive features. This analysis was possible considering the target treatment under study (corticosteroids) was not used for cluster derivation. Therefore, any further impact can be seen as unbiased and independent from former analyses. Discrete variables were expressed as counts (percentage) and continuous variables as means with standard deviation (SD) or medians and percentile range 25-75% (p25-75). For patient demographics and clinical characteristics, differences between groups were assessed using the chi-squared test and Fisher's exact test for categorical variables, and the Student t test or the Mann-Whitney U test for continuous variables. Inter-hospital variation in corticosteroids treatment was assessed by multilevel conditional logistic modelling (19) with patients nested in each hospital and by to calculate the intraclass correlation coefficient (ICC). The ICC quantifies the degree of homogeneity of the outcome within cluster and represents the proportion of the betweenhospital variation in the total variation. In the first step we assess the impact of corticosteroid treatment among the general population. An optimal fullmatching propensity score (PS) analysis was performed. This method performs optimal full matching, which is a form of sub-classification wherein all units, both treatment and control are assigned to a subclass and receive at least one match. Advantage of optimal full matching include is that the number of patients is not reduced (20) . We checked model performance with a cross validation and the patients were randomly divided into two subsets: (a) a "training set" with 1613 patients (80%), and (b) a "validation set" with 404 patients (20%). Subsequently, a logistic regression analysis (LRA) for ICU mortality was carried out with the matched population to assess factors independently associated with mortality in the whole population. The results are presented as Odds ratios (OR) and 95% CI and forest plots. In the second step, we assessed the impact of corticosteroid treatment in each predetermined phenotype. We defined cohort entry hierarchically on the basis of exposure, such as the first prescription for the drug under study. Thus, first, subjects who receive the treatment under study were considered ''exposed'' and entered the cohort at the time they started exposure. Following with all other subjects that are then considered unexposed, and their cohort entry is defined arbitrarily (ICU admission) by a comparison treatment. When considering patients who received corticosteroids upon admission or 48 hours prior ICU admission, we ensure that all patients have received the drug under study at the start of zero follow-up time (defined as ICU admission) and the immortal time bias is reduced. In addition, we performed a competing risks analysis (21) to solve immortal time bias and confirm our results. A Kaplan-Meier survival plot was generated to track ICU mortality over time for corticosteroid-treated and untreated patients in each clinical phenotype. The information provided by each variable regarding ICU mortality was defined using the Information Value (IV). A IV greater than 0.03 was considered clinically important and this variable was included in the LRA. In addition, a weighted Cox regression(wCox) was performed which yields unbiased estimates of average hazard ratios (HR) in case of non-proportional hazards (22) . Finally, to investigate the association between baseline (ICU admission) variables and corticosteroid use; a LRA was performed with variables of clinical interest and all significant covariates in the univariate analysis. The results are presented as odds ratios (OR) and 95% confidence intervals (CI). Data analysis was performed using R software (cran.r-project.org). Corticosteroids response in whole population: A propensity full matching A total of 2,017 critically ill patients were included. The median (p25-75) age was 64 (55-71) years, and 1,419 (70.3%) were men with an APACHE II of 13(10-17) and SOFA of 5 (3-7) scores. Characteristics of whole and phenotypes population are shown in Table 1 Therapeutic impact among the A phenotype, was assessed among 298 (55,5%) patients that received corticosteroids as co-adjuvant therapy for viral pneumonia (e- The unadjusted probability of survival (Kaplan-Meier plot) is shown in e- Figure 3 . No significant differences were observed (p=0.58) between groups. Twenty-eight variables were included in the wCox model (e- Table 7) and corticosteroids had no effect on ICU mortality (HR = 0.85 95%CI 0.55-1.33) (Figure 1 and e- Table 8 ). When a regression model for competing risk was performed (e- Figure 4 ), corticosteroid use remained as a factor not associated with mortality (SHR = 0.85 [95% CI 0.55-1.83). No significant differences were observed in laboratory findings or clinical characteristics of patients that received or not corticosteroids (e- Table 4 ), except for white blood cell counts(WBC), serum ferritin and the number of patients with more than 2 quadrant infiltrates in chest x-ray, more frequent in patients that received corticosteroid. These variables plus APACHE II, SOFA, age, IMV, obesity and CRP were included in LRA. Only presence more than 2 quadrant infiltrates in chest x-ray (OR= 1.5 ;95%CI 1.05-2.16) was associated with use of corticosteroids. (e- Table 9 ) Therapeutic impact among the B phenotype, was assessed among 338 (54,2%) patients that received corticosteroids. (e- VAP was more frequent in patients with (18.6%) than without corticosteroids treatment (11.9%, p=0.02). Conversely, corticosteroid treatment was not associated with mortality (e- Table 10 ). The unadjusted probability of survival (Kaplan-Meier plot) is shown in e- Figure 5 . No significant differences were observed between groups (p=0.58). Twenty variables were included in the wCox model (e- Table 7 ) that confirmed no association between corticosteroid and ICU mortality (HR= 0.72, 95%CI 0.49-1.05; p=0.096) (Figure 2 and e- Table 11 ). The multivariate regression model for competing risk (e- Figure 6 ), suggest that corticosteroid use was associated with outcome (SHR = 0.65 [95% CI 0.46-0.91). No significant differences were observed in laboratory findings or clinical characteristics of patients that received or not corticosteroids (e- Table 12 ). Therapeutic impact among the C phenotype, was assessed among 535 (62.4%) patients that received corticosteroids (e- Table 13 ). The unadjusted probability of survival (Kaplan-Meier plot) is shown in e- Figure 7 . No significant differences were observed (p=0.06). Twenty variables were included in the wCox model (e- Table 7 ) and corticosteroid treatment was J o u r n a l P r e -p r o o f 11 associated with a protected effect (HR 0.75, 95%CI 0.58-0.98; p=0.03) for ICU mortality (Figure 3 and e- Table 14 ). The competing risk regression model (e- Figure 8) This represents the first built machine learning model used to assess the effect of corticosteroids therapy according to pre-defined clinical phenotypes among a large cohort of critically ill patients with severe COVID-19 disease. The main finding of our study is that the use of corticosteroids was not associated with improved outcomes in all critically ill patients with COVID-19 at moderate dose. The challenge in developing optimal treatment strategies is the extreme heterogeneity of presentation in COVID-19 patients who are critically ill (15) (16) . Consequently, our study suggests that only clinical phenotypes with a high degree of systemic inflammation, such as the defined phenotype C, may have an early benefit from steroid treatment. Benefits offered by corticosteroids in attenuating immune dysregulation must be balanced with their inhibitory effect on the immune response needed to control viral replication, as well as risk of opportunistic infections and associated side-effects (13, 14) . Specifically, our results show a higher incidence of VAP in patients who have received corticosteroids in B and C phenotypes. Data from the RECOVERY Trial (8) and WHO meta-analysis (11), supported the administration of 6 mg dexamethasone for all patients with COVID-19 who required oxygen supplementation or IMV. However, the role of corticosteroids in the treatment of COVID-19 remains controversial (23) (24) (25) (26) (27) (28) (29) . A recent study in France (30) comparing first vs second wave reported that, despite of the systematic and early administration of glucocorticoids in the second wave, the ICU mortality (50% vs. 52%, p = 0.96) and duration of ICU stay did not differ between the two waves. In contrast, Wu C et al. (31) observed in 380 patients that, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS. However, it should be noted that this study only included patients with ARDS, and corticosteroids were initiated 13 days after symptom and this is not the usual clinical practice. 12 Chen et al (15) observed presence of two phenotypes (hypo and hyper-inflammatory) among COVID-19 patients. Interestingly, after applying a marginal structural modeling, the association between corticosteroid therapy and 28day mortality was only observed in patients with the hyper-inflammatory phenotype. These findings are consistent with our results, where only the phenotype C (with a higher inflammatory status), seem to have benefit from corticosteroid treatment. This observation is contrary to the current recommendation of dexamethasone treatment according to the RECOVERY trial (8) , that showed that the mortality from COVID-19 was lower among patients who were randomized to receive dexamethasone than among those who received the standard of care. Several limitations have been reported since its publication (2, 3, 32, 33) . Possibly the most important limitations are the lack of an adjustment according to severity of illness to minimize potential bias and that mortality has been censored at 28 days, and no data have been published from the mortality at ICU or Hospital discharge. Survival benefit of corticosteroids (8) appeared greatest among patients who required IMV. These findings are consistent with our results, as between 70-80% of patients in phenotypes B and C required ventilation and then could benefit from steroids. In the other hand, in the RECOVERY trial (8) a favorable effect on survival was evident with the use of steroids treatment among patients who only required supplemental oxygen. This sub-group of patients can be said to represent a similar profile to that of the A Phenotype from our study, where more than 80% of patients received only supplemental oxygen at ICU admission. However, we do not observe the impact of corticosteroid treatment on survival in this phenotype and our results strongly suggest that corticosteroid treatment should not be administered to patients who do not require mechanical ventilation independently of their hypoxemia level. Differences in results could be due to our patient adjustment modelling according to severity in illness and the absence of stratification and incomplete information about some factors associated with outcome in the RECOVERY trial may have resulted in imbalance between the treated and control (26) . In addition, a recent prospective study (34) with more than 3000 elderly critically ill COVID-19 patients, observed an independent association of steroid use with increased 30-days mortality after multivariable adjustment (aOR 1.60 95%CI 1.26-2.04). However, some study limitations should be noted. First, although phenotypes were found to be generalizable in our population (after validation), risk factors and characteristics that pre-defined these clinical phenotypes were derived initially from data at ICU admission of a multicenter observational study in Spain. However, at the same time these risk factors are similar to those that have been reported by other investigators (31-33, 35,36) which suggests its applicability to other populations. Second, only routinely available clinical data at ICU admission was used to identify risk factors and clinical phenotypes, and the inclusion of other data related to clinical evolution of patients in the ICU could change risk factors or phenotype assignments. However, our objective was to study early risk factors and phenotypes at ICU admission that may allow for early treatment implementation and as a result improve patient outcome. J o u r n a l P r e -p r o o f 13 Third, this is a sub-analysis conducted following the author's primary observational study in order to consider only segmental measured confounders. The authors are aware of the limitations presented by the exclusion of other residual measured confounders and unmeasured confounders that could not be included fully. Fourth, we cannot affirm that an echocardiographic assessment has been carried out in all patients, so the incidence of cardiac dysfunction may be higher than that observed. This incidence should be considered with caution. Finally, this study did not collect data that could assess the impact of ethnicity, socioeconomic factors o long-term complications. These factors may play a role in the prevalence of pre-existing comorbidities and mortality due to COVID-19. Our findings warn against the widespread use of corticosteroids in all critically ill patients with COVID-19 according to the moderate dose and suggests the need to determine within each phenotype what subset of patients may really benefit from treatment. Judith Marín-Corral, Lorena Forcelledo Espina and Immaculada Vallverdú had substantial contributions to conception and design of the work Josep María Bonell Goytisolo, Susana Sancho Chinesta, Virgina Fraile Gutierrez, Angel Estella and Lorenzo Socias Crespi had substantial contribution for data acquisition Judith Marín-Corral, Antonio Alabaya Moreno and Angel Estella had substantial contribution for data analysis and interpretation of data for the work Josep Gómez and Emili Díaz drafting of the manuscript Acute respiratory distress syndrome The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19 Ready for the winter? Discussion on "Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection Corticosteroid therapy for critically ill patients with middle east respiratory syndrome Corticosteroids as adjunctive therapy in the treatment of influenza (Review) Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study Dexamethasone in Hospitalized Patients with Covid-19 Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome COVID-19) Treatment Guidelines COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the Homogeneous cluster analysis Keep Calm and Learn Multilevel Logistic Modeling: A Simplified Three-Step Procedure Using Stata, R, Mplus, and SPSS Optimal full matching for survival outcomes: a method that merits more widespread use A Proportional Hazards Model for the Subdistribution of a Competing Risk Weighted Cox Regression Using the R Package coxphw Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: Meta-analysis The use of corticosteroid as treatment in SARS was associated with adverse outcomes: A retrospective cohort study Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis Corticosteroids in severe COVID-19: a critical view of the evidence Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials COVID-19: does one drug fits all? Med Intensiva Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis Early adoption of critical care interventions is unjustifiable without concomitant effectiveness study Pros and cons of corticosteroid therapy for COVID-19 patients Steroid use in elderly critically ill COVID-19 patients Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the US Clinical features of patients infected with 2019 novel coronavirus in Wuhan Alexis Garduno, MSc provided a factual review and helped edit the manuscript and the COVID-19/SEMICYUC Working Group (complete list of investigator in Appendix 2) The corresponding author (Alejandro Rodríguez) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of the manuscript. The views expressed in this article are those of the authors and not necessarily those of the SEMICYUC.